Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma

  • J Invest Dermatol. 2024 Oct 1:S0022-202X(24)02160-2. doi: 10.1016/j.jid.2024.07.037.
Antoine Méant  1 ,  Omar Moussa  1 ,  Benjamin Lebeau  2 ,  Christophe Gonçalves  3 ,  Vincent R Richard  4 ,  Feiyang Cai  1 ,  Sathyen A Prabhu  1 ,  Marios Langke  1 ,  Elizabeth M Guettler  3 ,  Jie Su  3 ,  Natascha Gagnon  3 ,  Rene P Zahedi  5 ,  Christoph H Borchers  6 ,  Wilson H Miller Jr  7 ,  Sonia V Del Rincón  8 ,  Michael Witcher  9
Affiliations
  • 1. Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada.
  • 2. Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
  • 3. Lady Davis Institute, Jewish General Hospital, Montréal, Canada.
  • 4. Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada.
  • 5. Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada; Manitoba Centre for Proteomics and Systems Biology, University of Manitoba, Winnipeg, Canada.
  • 6. Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada.
  • 7. Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada.
  • 8. Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada. Electronic address: [email protected].
  • 9. Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada. Electronic address: [email protected].
PMID: 39357785 DOI: 10.1016/j.jid.2024.07.037
Keywords
BET; FAK; MNK; Melanoma; TGM2.
Products